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ChemoresistanceMUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocar-
cinoma, and is considered as a potent target for cancer therapy. To control cancer progression, miRNAs became
very recently, major targets and tools to inhibit oncogene expression. Inhibiting MUC1 using miRNAs appears
thus as an attractive strategy to reduce cancer progression. However, potentmiRNAs and associatedmechanisms
regulating MUC1 expression remain to be identiﬁed. To this aim, we undertook to study MUC1 regulation by
miRNAs in pancreatic cancer cells and identify those with tumor suppressive activity. MiRNAs potentially
targeting the 3′-UTR, the coding region, or the 5′-UTR of MUC1 were selected using an in silico approach. Our
in vitro and in vivo experiments indicate that miR-29a andmiR-330-5p are strong inhibitors ofMUC1 expression
in pancreatic cancer cells through direct binding toMUC1 3′-UTR.MUC1 regulation by the other selectedmiRNAs
(miR-183, miR-200a, miR-876-3p and miR-939) was found to be indirect. MiR-29a and miR-330-5p are also
deregulated in human pancreatic cancer cell lines and tissues and in pancreatic tissues of KrasG12D mice. In
vitro,miR-29a andmiR-330-5p inhibit cell proliferation, cellmigration, cell invasion and sensitize pancreatic can-
cer cells to gemcitabine. In vivo intra-tumoral injection of these two miRNAs in xenografted pancreatic tumors
led to reduced tumor growth. Altogether, we have identiﬁed miR-29a and miR-330-5p as two new tumor sup-
pressive miRNAs that inhibit the expression of MUC1 oncogenic mucin in pancreatic cancer cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth leading cause
of death by cancer in Western countries and has a very poor prognosis
due to a late diagnosis and a lack of efﬁcient treatment. The ﬁve year sur-
vival rate is lower than 5%[1] and less than 20% of patients are entitled to
surgical resection [2]. The remaining 80% of patients present a locally ad-
vanced metastatic PDAC and may beneﬁt from palliative chemotherapy
based either on gemcitabine or FOLFIRINOX[3]. Despite this, PDAC prog-
nosis remains very poor and is highly resistant to chemotherapeutic
treatments. It is thusmandatory toﬁnd early biomarkers, to better under-
stand the molecular mechanisms underlying the disease and to identifyl inhibition; miRNA, microRNA;
ed region
Pierre Aubert Research Center,
nesis”, Rue Polonovski, 59045
an Seuningen).new therapeutic targets/tools to allow better disease management and
reduce pancreatic cancer progression.
The mucin MUC1 is a membrane-bound glycoprotein expressed at
the apical pole of normal polarized epithelial cells. In most epithelial
cancers including PDAC[4,5], MUC1 becomes oncogenic as it is
overexpressed, circumferentially delocalized around the tumor cell sur-
face and involved in several oncogenic pathways [6,7]. These properties
are the consequence of MUC1 interaction with the epidermal growth
factor receptor (EGFR) [8] which leads to the activation of several onco-
genic pathways (MAPK,Wnt/β-catenin) and increased cell proliferation
and survival [5,9,10]. We recently showed that MUC1 regulates human
PDAC cell proliferation via p42-44 MAPK and β-catenin pathways, de-
creases cell migration and invasion via MMP13 and sensitizes PDAC
cells to 5-ﬂuoro-uracil (5-Fu) and gemcitabine [5]. Others showed that
MUC1 may also regulate PDAC cell invasion through activation of
Stat3 [11,12] or PDGFR-β[13]. MUC1 also induces epithelial mesenchy-
mal transition (EMT) [14] and increases resistance to gemcitabine via
mechanisms dependent or not of Akt [15]. Finally, MUC1 was found as
one robust predictive marker of PDAC survival [16]. For all these
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tumorigenesis.
MUC1 is also translocated to the nucleus and associated with co-
factors and/or transcription factors on gene promoters to modulate
their expression. It was recently shown thatMUC1 regulatesmiRNA ex-
pression by bindingwith ZEB1 to the promoter of miR-200c resulting in
its inhibition and increased cell invasion and EMT[17]. Since miRNAs
regulate a large number of human genes, targeting regulatory mecha-
nisms mediated by miRNAs appears as an attractive strategy to inhibit
oncogenic proteins and propose new therapeutic approaches [18,19].
MiRNAs are 18 to 25 nucleotide long small non-coding RNAs which
regulate gene expression by binding to the 3′-UTR, 5′-UTR or coding re-
gions of their targetmRNAs [20].MiRNAs can also inhibit the translation
of their target or lead to the degradation of the mRNA and thereby pro-
tein expression [21]. MiRNAs are frequently deregulated in cancer, in-
cluding PDAC. Several studies have investigated the expression proﬁle
of miRNAs in PDAC but few of them have studied their biological role
and/or biological relevance [22,23]. We recently showed that miRNA
can effectively inhibit oncogenic mucin MUC4 in PDAC through the
overexpression of tumor suppressive miRNA [23] and the mucin
MUC13 was also shown to be directly regulated by miRNA in
PDAC[24]. This highlights the interest in targeting oncogenic mucins
in PDAC which are known to mediate PDAC progression but so far no
miRNAs have been identiﬁed as targeting the oncogenic mucin MUC1
in PDAC.
In this report, we undertook to identify miRNAs directly binding to
MUC1 regulatory regions including the 5′-UTR, the coding region and
the 3′-UTR. Using in vitro and in vivo approaches we show that miR-
29a and miR-330-5p are direct negative regulators of MUC1 expression
with tumor suppressive activities in pancreatic cancer. These two
miRNAs appear thus as potential new actors to reduce pancreatic cancer
progression.2. Material and methods
2.1. Cell culture
Capan-2, Capan-1, MiaPaCa-2 and BxPC-3 cell lines were purchased
from ATCC and Panc-1 from ECACC. PDAC cell lines were cultured as de-
scribed previously [5,23,25,26]. HPDE (Human Pancreatic Duct Epithelial)
cells were obtained from Dr M.S. Tsao (UHN, Toronto, Canada) and were
cultured as described previously [23].2.2. Establishment of stable cell lines
MiaPaCa-2 stable cell lines overexpressing miR-29a, miR-330-5p or
miR-neg (Table 1) were generated using lentiviral particles and miR-
330-5p, miR-29a or miR-NegpLenti4/TO/GFP-vectors and ViraPower
lentiviral packagingmix (Life Technologies) as described before [22,23].2.3. Transient cell transfections
Transfections of pre-miR™ (30 nM) miRNA precursors (Ambion) in
the cell lines were performed in 6-well plates during 48 h using
siPORT™ NeoFX™ Transfection Agent (Ambion) and OptiMEM®
(Life Technologies) according to the manufacturer's instructions. Pre-
miR™ miRNA precursor Negative Control #1 (Ambion) was used as
control. Total RNAs were extracted using miRNeasy Mini Kit with
Qiazol® (Qiagen). Total proteins were extracted as above. Three inde-
pendent experiments were performed in triplicate. For loss-of-function
studies in stable cell lines overexpressing miR-29a or miR-330-5p,
transfection of anti-miR™ (60 nM) miRNA inhibitors (Ambion) was
performed as indicated above. Anti-miR™ miRNA Inhibitor Negative
Control #1 (Ambion) was used as control.2.4. Cell proliferation, migration and invasion assays
Transfected cells or stable cell lines were seeded at 105 cells per well
in 6-well plates. Cells were counted every day using a Malassez
counting chamber using Trypan Blue exclusion dye (Life Technologies)
during 72 h for transfected cells and during 96 h for stable cell lines [5].
Invasion and migration assays were respectively performed using 24-
well Boyden chambers (8 μm pores) coated or not with Matrigel™
(Pharmingen, BD Biosciences). Brieﬂy, 5 × 104 to 105 cells were seeded
on the top chamber and FBS 10% (v/v) was used as a chemoattractant in
the bottom chamber for 24 h to 48 h [5]. Three independent experi-
ments were performed in triplicate.
2.5. Cytotoxicity assay
104 cells were seeded in 96-well plates during 24 h. Medium was
refreshed with gemcitabine, 5-Fu, oxaliplatin or SN-38 for 72 h. The vi-
ability of cells was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide assay (MTT, Sigma-Aldrich, Saint Quentin
Fallavier, France) as previously described [5]. Formazan crystals were
solubilized in dimethylsulfoxide (Sigma-Aldrich) and analyzed at
570 nm with a microplate reader (Bio-Rad).
2.6. Human pancreatic tissues
Human PDAC samples were obtained from the Lille University Hos-
pital with the approval of the Institutional Review Board. No patient re-
ceived either chemotherapy or radiotherapy before the surgical
resection except one patient.
2.7. Pdx-1-Cre; LStopL-KrasG12D mouse model of early pancreatic
carcinogenesis
Pdx1-Cre mice were obtained from the Mouse Models of Human
Cancer Consortium (MMHCC, USA). LStopL-KrasG12D mice were obtain-
ed fromDr D. Tuveson (Cambridge Research Institute, England). All pro-
cedures are in accordance with the guidelines of animal care ethical
committee (Comité Ethique Expérimentation Animale Nord Pas-de-
Calais, #AF042008) [23].
2.8. Subcutaneous xenografts
Subcutaneous (SC) xenografts (2 × 106 cells in 100 μl of RPMI 1640
or DMEM media) of miR-neg, miR-29a or miR-330-5p cell lines were
carried out with 100 μl of Matrigel™ (BD Biosciences) into the ﬂank of
severe-combined immunodeﬁcient (SCID) male mice (CB-17, Charles
Rivers) that were bred and maintained under pathogen-free conditions
(6 mice/group). Tumor development was followed weekly. The tumor
volume (mm3) was determined by calculating V=W2 × L in whichW
corresponds to the width (mm) and L to the tumor length (mm). Mice
were sacriﬁced 28 days after inoculation. All procedures were per-
formed in accordance with the guidelines and approved by the animal
care ethical committee (Comité Ethique Expérimentation Animale
Nord Pas-de-Calais, CEEA #122012) [5]. For intra-tumoral injection of
miRNAs, 2 × 106 cells for Capan-2 and 3 × 106 cells for MiaPaCa-2
were xenografted. After 10 days, 20 μg of miRNAs or miR-neg cloned
into the pCDNA6.2emGFP vector were injected into the SC tumors
(~300 mm3) using Exgen 500 (Euromedex) reagent and glucose 5%
(v/v) as described by the manufacturer's instructions. Tumors were
followed twice a week and mice were sacriﬁced 20 days after miRNA
injection.
2.9. Cloning of MUC1 3′-UTR, MUC1 5′-UTR/ﬁrst exon and luciferase assays
HumanMUC1 3′-untranslated region (UTR) orMUC1 ﬁrst exon con-
taining the 5′-UTR were cloned into the pGL3-promoter vector
Table 1
Characteristics of the primers used for qRT-PCR, cloning and site-directed mutagenesis.
Gene Forward/reverse Sequences 5′→ 3′
MUC1 Forward TGCCGCCGAAAGAACTACG
Reverse TGGGGTACTCGCTCATAGGAT
GAPDH Forward CCACATCGCTCAGACACCAT
Reverse CCAGGCGCCCAATACG
U6 Forward CGCAAGGATGACACGCAA
u6 Forward TGGCCCCTGCGCAAGGATG
hsa-miR-330-5p Forward TCTCTGGGCCTGTGTCTTAGGC
hsa-miR-29a Forward TAGCACCATCTGAAATCGGTTA
hsa-miR-183 Forward TATGGCACTGGTAGAATTCACT
hsa-miR-200a Forward TAACACTGTCTGGTAACGATGT
hsa-miR-876-3p Forward TGGTGGTTTACAAAGTAATTCA
hsa-miR-939 Forward TGGGGAGCTGAGGCTCTGGGGGTG
MUC1 3′-UTR XbaI Forward CGCTCTAGATCTGCCAACTTGTAG
Reverse CGCTCTAGATTGGCGCAGTGGGAGA
MUC1 3′-UTR mut miR-330-5p #1 Forward CCCAGGAGGACTGAAGCAACAAGCCCTGAGATAGC
Reverse GCTATCTCAGGGCTTGTTGCTTCAGTCCTCCTGGG
MUC1 3′-UTR mut miR-29a Forward CTGTTTGGGCTGGTGAGCTGGGAGTCACGGTGGGCCAATCACAGCCTCCTT
Reverse AAGGAGGCTGTGATTGGCCCACCGTGACTCCCAGCTCACCAGCCCAAACAG
MUC1 3′-UTR mut miR-330-5p #2 Forward CTCAGGTTCTTCAGGGCGCCGGCCCCTGCACCCTGTTT
Reverse AAACAGGGTGCAGGGGCCGGCGCCCTGAAGAACCTGAG
MUC1 5′UTR HindIII Forward CGCAAGCTTCCACCTCTCAAGCAGCCA
Reverse CGCAAGCTTCTGTAAGCACTGTGAGGAGC
MUC1 5′-UTR mut miR-876-3p Forward CCTCCCCACCCATTTCACTCTAACCATGACACCGGGCACC
Reverse GGTGCCCGGTGTCATGGTTAGAGTGAAATGGGTGGGGAGG
MUC1 5′-UTR mut miR-939 Forward GTGGTGGTGAAATGGGTTATAAGGGGGCAGAACAGATTCAGGCAG
Reverse CTGCCTGAATCTGTTCTGCCCCCTTATAACCCATTTCACCACCAC
LV-hsa-miR-29a Forward TGCTGTAGCACCATCTGAAATCGGTTAGTTTTGGCCACTGACTGACTAACCGATTTCATGGTGCTA
Reverse CCTGTAGCACCATGAAATCGGTTAGTCAGTCAGTGGCCAAAACTAACCGATTTCA
LV-hsa-miR-330-5p Forward TGCTGTCTCTGGGCCTGTGTCTTAGGCGTTTTGGCCACTGACTGACGCCTAAGACACACCCAGAGA
Reverse CCTGTCTCTGGGTGTGTCTTAGGCGTCAGTCAGTGGCCAAAACGCCTAAGACACAGGCCCAGAGAC
LV-hsa-miR-neg Forward AAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATTT
Reverse AAATGTACTGCGTGGAGACGTCAGTCAGTGGCCAAAACGTCTCCACGCGCAGTACATTT
2394 S. Tréhoux et al. / Biochimica et Biophysica Acta 1853 (2015) 2392–2403(Promega) usingXbaI orHindIII restriction sites (Biolabs) (Table 1). Mu-
tationswere performed using the QuickChange® XLsite-directedmuta-
genesis kit (Stratagene, Agilent Technologies) (Table 1). Luciferase
activity and protein assays were performed as previously described
[23,26]. Luciferase assays were carried out three times in triplicate.
2.10. Biotin pull-down assay
106 cells were transfected with miR-29a, miR-330-5p or scramble
3′-biotinylatedmiRNA (100nM) (Dharmacon, Thermo Scientiﬁc) as de-
scribed above. Biotin pull-down assays were performed in Capan-1,
Capan-2 and MiaPaCa-2 cell lines in triplicate in three independent se-
ries of experiments as previously described [23,27]. Pulled-downRNA
was directly extracted from the beads or from the input RNA using the
miRNeasy Mini kit (Qiagen). Reverse transcription and qRT-PCR were
then performed.
2.11. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Total RNAs including miRNAs from cells and formaldehyde-
ﬁxedparafﬁn-embedded tissues were extracted using miRNeasy Mini
Kit with Qiazol® (Qiagen) and RecoverAll™ Total Nucleic Acid Isolation
Kit (Ambion, Life Technologies) according to the manufacturer's in-
structions. RNA(1 μg) was reverse transcribed with the QuantiMiR Re-
verse Transcription Kit (System Biosciences, Ozyme). For mRNA, cDNA
was prepared as previously described [5,26]. qPCR was performed
using SsoFast Evagreen® Supermix (Bio-Rad) and the CFX96 real time
PCR system (Bio-Rad). Expression levels ofMUC1 and miRNAs of inter-
est were respectively normalized to GAPDH and human U6/mouse
u6 (Table 1). MiRNA universal primers were provided with thequantiMiR™ kit (System Bioscience, Ozyme). Expression levels
were calculated using the 2−ΔΔCt method. Three independent experi-
ments were performed.2.12. Protein extraction and Western-blot analysis
Total proteins were extracted, electro-transferred, immunostained,
and visualized as described before [5,23,26,28,29]. Antibodies used are
MUC1 (M8, 1/250, from Pr D. Swallow); β-actin (A5441 AC15, 1/5000)
from Sigma-Aldrich; cyclin D1 (sc-718, 1/250)and CDK6 (sc-177, 1/
250) from Santa Cruz; EGFR (#4267s, 1/500), Bcl-2 (#2872, 1/250),
phospho P53 (#9284, 1/500), P53 (#9282, 1/500), phospho p42–44
MAPK (#9101, 1/500), p42–44 MAPK (#9102, 1/500), phospho Stat3
(#9145, 1/250), Stat3 (#9139, 1/500), β-catenin (#8480s, 1/1000),
phospho AKT (#4060, 1/500), and AKT (#4691s, 1/500) from Cell Signal-
ing, Ozyme. The signal was detected using LAS 4000 apparatus (Fujiﬁlm).
Densities of bands were integrated using image J analysis software and
represented as histograms.2.13. Immunohistochemistry
Human pancreatic tissues, tumor xenografts andmousse tissueswere
ﬁxed in 10% (w/v) buffered formaldehyde, parafﬁn-embedded, cut at
4 μm thickness and applied on SuperFrost® slides (Menzel-Glaser, Ther-
mo Scientiﬁc). Histologywas assessed by staining tissues with Hematox-
ylin–Eosin. Manual immunohistochemistry (IHC) was carried out as
described [30] and automatic IHC was performed with an automated
immunostainer (ES, Ventana Medical System, Strasbourg, France) as de-
scribed [5,31]. Detection of MUC1 in human tissues and xenografts was
carried out with anti-MUC1 M8 Mab (1/50) [5] and in mouse tissues
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2.14. Statistical analyses
Statistical analyses were performed using Graphpad Prism 4.0 soft-
ware (Graphpad softwares Inc.). Data are presented as mean ± SD or
±SEM. Differences in the mean of samples were analyzed by the
student's t test or one way ANOVA test with selected comparison
using Tukey's HSDpost-hoc test or Wilcoxon signed-rank test. Differ-
ences less than 0.05 were considered signiﬁcant and were indicated
with an “*”. ** indicates p b 0.01, and *** indicates p b 0.001.
3. Results
3.1. In vitro regulation of MUC1 by miRNAs in PDAC cell lines
Using miRanda, miRWalk and mirBase softwares, we found one
potential binding site for miR-29a and two potential binding sites
for miR-330-5p on MUC1 3′-UTR (Fig. 1A). Additionally, we found
one binding site for miR-876-3p and miR-939 on MUC1 5′-UTR and
one binding site in the 3′-UTR and the ﬁrst exon of MUC1 for miR-
183 and miR-200a. Overexpression of these miRNAs in PDAC cells
induced a strong decrease of MUC1 expression compared to miR-
neg(Fig. 1B). Co-transfection of MUC1 3′-UTR and the miRNAs of in-
terest led to a signiﬁcant decrease of luciferase activity in the pres-
ence of miR-29a or miR-330-5p(Fig. 1C). Mutation of miR-29a or
miR-330-5p binding sites intoMUC1 3′-UTR led to luciferase activity
restoration for miR-29a andmiR-330-5p site #2 but not for miR-330-
5p site #1 (Fig. 1C). No signiﬁcant variation of luciferase activity was
found with any other miRNAs. To further validate the direct interac-
tion between miR-29a, miR-330-5p and MUC1 mRNA we used an
afﬁnity-based approach with biotinylated miRNAs. In Capan-2 cells,
we show a 1.5 fold enrichment of MUC1 mRNA for both miR-29a
and miR-330-5p pulldown (Fig. 1D). The same fold enrichments
were found in Capan-1 cell line (1.8 for miR-29a pulldown and 1.5
for miR-330-5p pulldown, not shown). In MiaPaCa-2 cell line, en-
richments were stronger with a 2.5-fold enrichment of MUC1
mRNA for miR-29a pulldown and 4.4-fold for miR-330-5p pulldown
(Fig. 1D). Altogether these results demonstrate that miR-29a and
miR-330-5p (site #2) negatively regulate MUC1 expression by
interacting directly with its 3′-UTR.
3.2. Expression of miR-29a, miR-330-5p and MUC1 in human and mouse
PDAC cells and tissues
Having shown in vitro that miR-29a andmiR-330-5p are direct neg-
ative regulators of MUC1 expression in PDAC cells, we undertook to
study their expression in human PDAC cell lines and ex vivo in human
and mouse pancreatic tissues. A decreased expression of miR-29a was
found in the ﬁve PDAC cell lines (MiaPaCa-2, Capan-1, Panc-1, BxPC-3,
and Capan-2) compared to normal HPDE cells (Fig. 2A).MiR-330-5p ex-
pression was decreased in MiaPaCa-2 and Capan-1 cells (Fig. 2A). Ex-
pression of MUC1 mucin in the different cell lines is also shown
(Fig. 2A, insert). Pancreatic expression was then studied in a pre-
clinical mouse model of pancreatic carcinogenesis (KrasG12D) develop-
ing PanIN preneoplastic lesions in which we found a mild decreased of
miR-29a and miR-330-5p expression compared to control mice
(KrasWT) (Fig. 2B) whereas Muc1 was overexpressed (Fig. 2C). In
human PDAC samples, a signiﬁcant decreased expression of miR-29a
and miR-330-5p was found compared to non-tumoral adjacent tissues
(Fig. 2D). This was correlated to overexpression and cytoplasmic delo-
calization of MUC1 (Fig. 2E). Altogether these results indicate a de-
creased expression of miR-29a or miR-330-5p, associated with MUC1
overexpression in human and mouse PDAC tissues.3.3. Biological properties of PDAC cells transiently overexpressing miR-29a
and miR-330-5p
To further study the functional activity of miR-29a and miR-330-5p,
transient overexpression of these miRNAs was realized in Capan-2,
MiaPaCa-2 and Capan-1 cell lines (Fig. 3A). MiRNA overexpression led
to a signiﬁcant decreased expression of both MUC1 mRNA (Fig. 3B)
and protein (Figs. 1B and 3C) levels in all cell lines. Simultaneous over-
expression of both miR-29a and miR-330-5p did not potentiate the ef-
fects. Overexpression of miR-29a or miR-330-5p in cells alone or in
combination induced a signiﬁcant decrease of cell proliferation
(Fig. 3D), cell migration (Fig. 3E) and cell invasion (Fig. 3F). Altogether
these results indicate that both miR-29a and miR-330-5p alter PDAC
cell proliferation, migration and invasion.
3.4. Biological properties of PDAC cells stably overexpressing miR-29a
and miR-330-5p
Having shown that miR-29a, miR-330-5p and MUC1 had an in-
verse proﬁle of expression in PDAC, and that these two miRNAs al-
tered biological properties of PDAC cells, we established stable cell
lines overexpressing either miR-29a or miR-330-5p in MiaPaCa-2
cells in order to further assess their biological effects (Fig. 4A). A
strong decrease of MUC1 mRNA and protein expression was ob-
served in stable cell lines compared to control cells (Fig. 4B & C).
Cells overexpressing miR-29a or miR-330-5p showed a statistically
signiﬁcant decrease of cell proliferation (Fig. 4D), migration and in-
vasion (Fig. 4E). Accordingly to the decreased of cell proliferation,
we observed a decrease of phospho p42–44 MAPK, cyclin D1 and
β-catenin expression in the two cell lines and a decrease of CDK6
and EGFR in cells overexpressing miR-29a(Fig. 4C). Finally, we per-
formed loss-of-function studies using anti-miRNAs and measured
impact on cell proliferation (Fig. 4F) and cell migration/invasion
(Fig. 4G). The results indicate a statistically signiﬁcant increase of
cell proliferation (Fig. 4F), migration and invasion (Fig. 4G) for
both anti-miRNAs. Altogether, these results indicate that PDAC cells
overexpressing transiently or stably miR-29a or miR-330-5p harbor
an altered PDAC cell behavior that is less tumorigenic.
3.5. Effect of miR29a and miR-330-5p on PDAC cell chemosensitivity,
survival and apoptosis
PDAC being an extremely chemoresistant cancer, we undertook
to evaluate miR-29a and miR-330-5peffects on PDAC cell chemo-
sensitivity. Measurement of cell survival following drug treatment
indicated that overexpression of miR-29a or miR-330-5p led to a
signiﬁcant decrease of cell viability following treatment with
gemcitabine whereas no signiﬁcant variation was found with drugs
of the FOLFIRINOX protocol (oxaliplatin, 5-Fu or SN-38) (Fig. 5A).
IC50 determination also indicated that stable cell lines overexpress-
ing miR-29a (~383 nM) or miR-330-5p (~239 nM) were more sensi-
tive to gemcitabine than miR-neg cells (~646 nM) (Fig. 5B). We then
measured the activation of major signaling markers/pathways in-
volved in cell survival or cell apoptosis in these cellular models. We
found an increased level of apoptotic marker phospho-P53 and a de-
crease of anti-apoptotic marker Bcl-2 together with a decrease of
phospho-AKT and phospho-Stat3 (Fig. 5C). Altogether, these results
indicate that PDAC cells overexpressing miR-29a or miR-330-5p are
more sensitive to gemcitabine, survive less and are more apoptotic.
3.6. In vivo biological effects of miR-29a and miR-330-5p on PDAC
tumor properties
Having shown in vitro that miR-29a and miR-330-5p possessed
tumor suppressive activities, we undertook to evaluate their activity
in vivo. To this aim, subcutaneous (SC) xenografts of Capan-2 and
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Fig. 1.MUC1 regulation by miRNAs in PDAC cell lines. (A) Sequence ofMUC1 3′-UTR and position of miR-29a, miR-330-5p, miR-183, and miR-200a potential binding sites (left) and se-
quence ofMUC1 ﬁrst exon containing its 5′-UTR and position of miR-876-3p, miR-939, miR-183, and miR-200a potential binding sites (right). (B) Study of the expression of MUC1 in
Capan-2 cells transfected with the miRNA of interest or miR-neg by Western-blot. (C) Measurement of luciferase activity in Capan-2 cells co-transfected with miRNAs of interest and
MUC1 3′-UTR orMUC1 Exon1 containing the 5′-UTR cloned into pGL3 promoter luciferase-reporter vector. The miR-neg luciferase activity is arbitrarily set to 1. (D) Biotinylated miR-
29a or miR-330-5p or scramble miRNAs (miR-neg) were transfected in Capan-2 (left panel) and MiaPaCa-2 (right panel) cells. Enrichment ofMUC1 mRNA in miRNA pulldown was
assessed by qRT-PCR. TheMUC1/GAPDH ratio was calculated and normalized to the input.
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tumoral injection of the miRNA of interest. A signiﬁcant decrease of
Capan-2 (p b 0.05) and MiaPaCa-2 (p b 0.001) tumor growth wasfound when compared to control miR-neg (Fig. 6A). Tumor weights
were also signiﬁcantly decreased when injected with miR-29a in
Capan-2 (p b 0.05) or both miRNAs in MiaPaCa-2 (p b 0.05) (Fig. 6B).
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PDAC
Fig. 2.MiRNA expression in PDAC cells and tissues. (A) Expression of miRNAs in HPDE, MiaPaCa-2, Capan-1, Panc-1, BxPC-3, and Capan-2 cell lines was studied by qRT-PCR. MiRNA ex-
pressionwasnormalized to controlU6RNA.MiRNA level in normal pancreatic ductal cells HPDEwas arbitrarily set to 1. Insert: expression ofMUC1mucin byWestern-blotting. (B) MiRNA
expression in control KrasWT and KrasG12D mice studied by qRT-PCR. MiRNA expression was normalized to control u6 RNA. Expression in KrasWT mice was arbitrarily set to 1. (C) MUC1
expression by IHC in control KrasWT and inKrasG12Dmice. (D) MiR-29a andmiR-330-5p expression in a cohort of 18 patientswith PDAC byqRT-PCR.MiRNAexpressionwas normalized to
controlU6 RNA and expressed as a ratio of PDAC/non-tumoral adjacent tissues (control). (E) MUC1 expression by IHC in non-tumoral adjacent tissues (control) and in tumors (PDAC). As
an illustration, results with patient #1 are shown.
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miR-330-5p were also carried out, in which a signiﬁcant decrease of
tumor growth was observed (p b 0.01) (Fig. 6C). This was correlated
to a strong decrease of MUC1 expression (Fig. 6D). Altogether these re-
sults indicate that in vivo miR-29a andmiR-330-5p possess tumor sup-
pressive activities on PDAC tumors.4. Discussion
Pancreatic Ductal Adenocarcinoma suffers from a very poor progno-
sis and absence of early detection and efﬁcient therapy [2,19]. Recently,
miRNAs have emerged as very attractive molecules to target cancer
since they regulate many genes encoding oncogenic proteins [20]. In
Fig. 3. Biological properties of PDAC cells transiently overexpressingmiR-29a ormiR-330-5p. (A) Expression ofmiR-29a andmiR-330-5p wasmeasured after transient overexpression in
Capan-2, MiaPaCa-2 and Capan-1 cells by qRT-PCR. MiRNA expression was normalized to control U6 RNA. The miR-neg expression was arbitrarily set to 1. (B) Analysis ofMUC1mRNA
expression in Capan-2, MiaPaCa-2 and Capan-1 cells transfected with pre-miRNAs of interest or miR-neg by qRT-PCR.MUC1 expression was normalized to control GAPDH. The miR-neg
expressionwas arbitrarily set to 1. (C) Analysis ofMUC1 protein expression inMiaPaCa-2 and Capan-1 cells transfectedwith pre-miRNAs of interest ormiR-neg byWestern-blot. (D) Cell
proliferation, (E) cellmigration and (F) cell invasionweremeasured in Capan-2,MiaPaCa-2 and Capan-1 cells transfectedwith pre-miRNAs. (E, F) Results are expressed as a percentage of
migration or invasion in miR-transfected cells compared to the control miR-neg (100%).
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miRNAs but their exact biological role and the identiﬁcation of their tar-
gets remain largely unknown [22,23]. In this report, we have identiﬁed
miR-29a and miR-330-5p as two new miRNAs directly targeting the 3′
UTR of MUC1 oncogenic mucin in PDAC cells and demonstrate that
these two miRNAs display tumor suppressive activities in PDAC bothin vitro and in vivo. We thus propose miR-29a and miR-330-5p as ap-
propriate targets to inhibit MUC1 expression in order to slow-down
pancreatic carcinogenesis and develop new potential therapeutic tools.
MiR-29a and miR-330-5p were shown to inhibit MUC1 expression
by directly binding to its 3′-UTR but interestingly we have also identi-
ﬁed additional potential binding sites for miR-29a and miR-330-5p
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Fig. 5. Chemosensitivity of PDAC cells overexpressing miR-29a or miR-330-5p. (A) Cells were treated for 72 h with different concentrations of gemcitabine, 5-Fu, oxaliplatin or SN-38
before cell survival measurement. (B) IC50 rates after 72 h of gemcitabine treatment. (C) Analysis of phospho-AKT, AKT, phospho Stat3, Stat3, phospho-P53, P53 and Bcl-2 expression
byWestern-blot. Density of eachmarker was measured and protein of interest/β-actin ratio is indicated. Expression inmiR-Neg cells was arbitrarily set to 1. Phospho AKT/AKT, phospho
Stat3/Stat3, and phospho P53/P53 ratios were determined and represented as histograms.
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also involve the binding of these twomiRNAs to additional regions. The
validation of these sites will be of particular interest especially because
it was shown that MUC4 andMUC16 oncogenic membrane-boundmu-
cins are regulated by miRNAs through their coding regions [32]. This
could thus represent a general mechanism of mucin gene regulation
by miRNAs.
In breast cancer cells, MUC1 is regulated by miR-145[33], miR-
1226[34] and miR-125b[35]. In this report we show that, MUC1 is di-
rectly regulated by miR-29a and miR-330-5p and indirectly regulated
by miR-876-3p, miR-939, miR-183 and miR-200a in PDAC cells. MiR-
183 and miR-200families are EMT inhibitors and favor epithelialFig. 4. Biological properties of PDAC cells stably overexpressingmiR-29a ormiR-330-5p. (A) Ex
expression was normalized to control U6 RNA. ThemiR-neg expression was arbitrarily set to 1.
control GAPDH. ThemiR-neg expressionwas arbitrarily set to 1. (C) Analysis of MUC1, EGFR, β-
ern-blot. Density of eachmarker wasmeasured and protein of interest/β-actin ratio is indicated
and (E) cellmigration and invasion. (E) Results are expressed as a percentage of migration or in
proliferation (F) and cellmigration/invasion (G) inMiaPaCa-2 stable cell lines overexpressingm
or anti-miR-330-5p at 60 nM.differentiation [36] by inhibiting the Wnt/β-catenin signaling pathway
[37,38]. The membrane-bound mucin MUC1 is an epithelial marker of
polarized epithelial cells [4,6,7] but aberrant overexpression of MUC1
in cancer cells is correlated with an induction of EMT through the
Wnt/β-catenin signaling pathway [14]. The indirect inhibition of
MUC1 by miR-183 and miR-200a could be an additional mechanism
to inhibit EMT in PDAC. The role of miR-876-3p and miR-939 is hardly
known in cancer. The indirect mechanisms leading to MUC1 inhibition
will have to be identiﬁed in future studies. The identiﬁcation of predict-
ed partners such as EGFR, cyclin D1, and Stat3, indirectly regulating
MUC1, that are potential targets of miR-876-3p or miR-939 (personal
communication) suggests that targeting these miRNAs could representpression ofmiR-29a andmiR-330-5p in stable cell lines wasmeasured by qRT-PCR. MiRNA
(B) Analysis ofMUC1mRNA expression by qRT-PCR.MUC1 expression was normalized to
catenin, cyclin D1, phospho-p42–44MAPK, p42–44MAPK, and CDK6 expression byWest-
. Expression inmiR-neg cells was arbitrarily set to 1. (D) Measurement of cell proliferation
vasion of cells compared to the control miR-neg orMock cells (100%). Measurement of cell
iR-29 (toppanel) ormiR-330-5p (bottompanel) treatedwith anti-miR-neg, anti-miR-29a
Fig. 6. In vivo effects of miR-29a and miR-330-5p on PDAC tumor properties. Subcutaneous (SC) xenografts of Capan-2 (left panel) and MiaPaCa-2 (right panel) cells in SCID mice. Intra-
tumoral injection ofmiR-neg,miR-29a ormiR-330-5pwas performed 10 days post-xenografting (~300mm3). (A) Tumor growth (mm3)wasmeasured for 20 days aftermiRNA injection.
(B) Tumor weight (g) was measured at the sacriﬁce in Capan-2 (left panel) and MiaPaCa-2 (right panel) tumors injected with miR-neg, miR-29a or miR-330-5p. (C) SC xenografts of
MiaPaCa-2 cells stably overexpressing either miR-neg, miR-29a or miR-330-5p in SCID mice. Tumor growth (mm3) was measured during 20 days. (D) MUC1 protein expression by
IHC in SC tumors.
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exclude that miR-145, miR-1226 and miR-125b known to regulate
MUC1 in breast cancer cell linesmay also beMUC1 regulators in pancre-
atic cancer cells. Somepreliminary data obtained in our laboratory seem
to indicate that these miRNAs also downregulate MUC1 in pancreatic
cancer cells (personal communication).
We also demonstrate that miR-29a and miR-330-5p inhibit MUC1
expression and deregulate signaling pathways as well as PDAC cell pro-
liferation, migration, invasion and tumor growth. It is well-established
that MUC1 is involved in these pathways [5,39]. These mechanisms
may involve p42–44 MAPK, cyclin D1 and β-catenin as we recently
showed that inhibiting MUC1 in PDAC cells altered these pathways
[5]. It was also proposed that the overexpression of miR-29a decreased
β-catenin expression and cell proliferation in non-small cell lung cancer
[40]. The same effect was observed in miR-29a overexpressing PDAC
cells and in PDAC cells lacking MUC1 [5]. The overexpression of miR-
330-5p in colorectal cancer cells was previously shown to decreasecell proliferation through direct regulation of Cdc42 and decrease ex-
pression of cyclin-D1[41]. The same effect was observed in PDAC cells
overexpressingmiR-330-5p.Moreover, the fact thatmiR-29a alters pro-
liferationmore profoundly thanmiR-330-5p suggests that bothmiRNAs
have additional targets. In that matter, we observed the decreased ex-
pression of CDK6 and Bcl-2 two known targets of miR-29a when it
was overexpressed [42,43]. Altogether these data are in favor of a
tumor suppressor activity for these two miRNAs in PDAC cells.
Contrarily to miR-330-5p, overexpression of miR-29a had a modest
effect on PDAC cell invasion. This could result from the inhibition of
CDK6 that we observed in these cells, loss of CDK6 being a marker of
several PDAC cell line invasiveness [44]. This may also be due to other
properties of miR-29a that depend on the cellular context: increased in-
vasion through MMP2, E-cadherin and KLF4 in colorectal cancer cells
[45], decreased invasion in gastric [46], lung and pancreatic cancer
cells [47], or decreased invasion and metastasis probably through the
inhibition of CEACAM6 in pancreatic cancer [48].
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5p sensitizes PDAC cells to gemcitabine and induces a decrease of Akt
pathway activation. Interestingly, MUC1 is known to mediate PDAC cell
chemoresistance to gemcitabine by regulating MRP1 gene expression
through thePI3K/AKTpathway [5,15]. Although,miR-29a overexpression
was previously shown to induce gemcitabine resistance in other PDAC
cells (BxPC-3 and Panc-1) through theWnt/β-catenin signaling pathway
[49], other results in lung cancer cells indicate that overexpression of
miR-29a inhibitsWnt/β-catenin signaling and β-catenin expression [40].
The same effectswere described in PDAC cells lackingMUC1 [5]. Interest-
ingly, it was also shown that miR-29a inhibits AKT expression [50] sensi-
tizes ovarian cancer cells to cisplatin [51], and that miR-330-5p
overexpression decreased AKT phosphorylation in colorectal cancer
[41]. The decrease of AKT expression suggests a MUC1/AKT dependent
mechanism mediating miR-29a/miR-330-5p effects on MiaPaCa-2 cell
sensitivity to gemcitabine. Altogether, these data highlight the complex
role of these miRNAs in chemoresistance processes triggered by cancer
cells thatmost likely are cell-speciﬁc. Further investigationwill be needed
to decipher the mechanisms underlying the sensitivity of PDAC cells to
chemotherapeutic drugs in relation withMUC1, miRNA and AKT expres-
sion. Moreover, we also showed that overexpression of miR-29a or miR-
330-5p increases P53 activity as previously proposed for miR-29a[52]
and decreases Bcl-2 expression like it was previously proposed in PDAC
cells lacking MUC1 [5] suggesting an involvement of these two miRNAs
in cell apoptosis.
We also show that miR-29a and miR-330-5p are deregulated in
human PDAC cell lines and tissues, and in the KrasG12Dpre-clinical
mouse model of pancreatic cancer. Expression studies in a cohort of 18
human PDAC tissues showed inhibition of miR-29a and miR-330-5p
which is in accordancewith previous studies showing thatmiR-29a is fre-
quently deregulated in cancerous tissues. This conﬁrms the potential of
miR-29a as a target for cancer therapy as it was previously proposed
[53] and highlights the interest for miR-330-5p in PDAC.5. Conclusion
In conclusion, we show (i) that MUC1 is regulated by miRNAs in
PDAC cells by direct and indirect mechanisms, (ii) that miR-29a and
miR-330-5p are deregulated in PDAC and that PDAC cells overexpress-
ing transiently or stably either miR-29a or miR-330-5p possess similar
biological properties: in vitro decreased proliferative, migrating, and in-
vasive properties and in vivo decreased tumor growth, and (iii) that
miR-29a and miR-330-5p sensitize PDAC cells to gemcitabine. Based
on that, we propose that tumor suppressive miR-29a and miR-330-5p
may represent attractive targets to inhibit the expression of the onco-
genic MUC1 mucin and decrease pancreatic cancer progression.Author contribution
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